NeuroLens: Lenses use a contoured prism to treat misalignment in vision

• Date :
• 2    
  0

Panoptes Pharma: One Molecule, Two Indications

• Date :
• 1    
  0

Why Ophthalmology Is Ready for Artificial Intelligence

• Date :
• 0    
  0

Oyster Point Takes Different Route to Treat Dry Eye

• Date :
• 0    
  0

MC2 Therapeutics Takes Next Step in Europe

• Date :
• 0    
  0

Silk Technologies Takes Novel Approach to Treat Dry Eye with Biological Drug

• Date :
• 0    
  0

Sight Sciences Reports Pilot Study Results

• Date :
• 0    
  0

Eyevensys_ _Biofactory_ Platform

• Date :
• 0    
  0

iSTAR Medical Pursues _Next-Gen_ MIGS Device

• Date :
• 0    
  0

Mati Therapeutics Punctal Platform Targets Multiple Indications

• Date :
• 0    
  0

Aura Biosciences Previews Early Trial Results

• Date :
• 0    
  0

Presbyopia Therapies and the _Holy Grail_ of Presbyopia Treatment

• Date :
• 0    
  0

Untreated Corneal Disease Draws Interest of Trefoil Therapeutics

• Date :
• 0    
  0

Verana Health Aims to Take Health Analytics to Next Level

• Date :
• 0    
  0

Ophthorobotics Working on Robotics for Ocular Injections

• Date :
• 0    
  0

Tracery Ophthalmics: Harnessing AI for Precision Drug Development

• Date :
• 0    
  0

Gobiquity: GoCheck Kids Brings Pediatric Vision Screening to a Smartphone

• Date :
• 0    
  0

GenSight: Disruptive Gene Therapy in Retinal and Neurodegenerative Disease

• Date :
• 0    
  0

Opthea: OPT-302 (VEGF-C/D trap) for Combination Treatment in nAMD and DME

• Date :
• 0    
  0

REGENXBIO: AAV Gene Therapy Company With 4 Internal Clinical-Stage Programs

• Date :
• 0    
  0

Ophthotech: Transformative Gene Therapy and Novel Therapeutics in Retina

• Date :
• 0    
  0

EyePoint: Transforms Into Commercial-Stage Organization with Dexycu and Yutiq

• Date :
• 0    
  0

Oxurion: Developing Innovative Therapies for Diabetic Eye Disease

• Date :
• 0    
  0

Eyenovia: Enabling smart delivery of ophthalmic pharmaceuticals

• Date :
• 0    
  0

Allegro Ophthalmics Preps for Phase III of Risuteganib

• Date :
• 0    
  0

Diabetic retinopathy, AMD, retina, Ophthalmology, Innovation

• Date :
• 0    
  0

Graybug_s Goal: Extend Treatment to 6 Months or More

• Date :
• 0    
  0

AGTC Pipeline: Four in Hand, One on the Way

• Date :
• 0    
  0

LumiThera_s Novel Light-Based Treatment for Dry AMD

• Date :
• 0    
  0

Gemini Therapeutics Looks to Leverage Precision Medicine to Treat Dry AMD

• Date :
• 0    
  0

Translatum Medicus Preps for First Dry AMD Trial

• Date :
• 0    
  0

Encapsulated Therapies Key for Neurotech

• Date :
• 0    
  0

Eyedaptic_s Designs for Augmented-Reality Vision Aid

• Date :
• 0    
  0

ArcScan: Insight 100 system allows imaging behind the iris

• Date :
• 0    
  0

AMPLIFY Enables Kala Pharmaceuticals_ Pipeline

• Date :
• 0    
  0

PowerVision: First true shape changing, fluid-driven accommodating IOL

• Date :
• 0    
  0

Mynosys: Automated capsulotomy device Zepto allows 360-degree IOL coverage

• Date :
• 0    
  0

Omega Ophthalmics: Gemini Refractive Capsule implant keeps capsular bag open

• Date :
• 0    
  0

ReNeuron: Using hRPCs to treat inherited retinal degenerative diseases

• Date :
• 0    
  0

Aerie: Bringing Rhopressa and Roclatan into US glaucoma marke

• Date :
• 0    
  0

OIS Co-Chair Cunningham Recounts Banner Year

• Date :
• 0    
  0

OIS Index: What Events Could Drive Ophthalmology Stocks Up in 2019?

• Date :
• 0    
  0

What Should Concern You About the IPO Market?

• Date :
• 0    
  0

Follow the Rise of AI and Analytics in Ophthalmology

• Date :
• 0    
  0

Hemera Has Dry AMD in Its Sights

• Date :
• 0    
  0

17e Congrès de l'European Glaucoma Society - EGS 2026

• Date :
• 801    
  0

15ème Congrès de la Société Francophone de basse vision - ARIBa 2025

• Date :
• 699    
  0

18ème Congrès des Journées Alsaciennes d'Ophtalmologie - JAO 2025

• Date :
• 581    
  0

Conférence de l'American Academy of Ophthalmology - AAO 2025

• Date :
• 921    
  0

18e Cours de l'European Glaucoma Society (EGS)

• Date :
• 693    
  0